The heterogeneity of GS expression in GBM has been previously reported.[11] GS protein levels vary among GBM patients, with about 30% exhibiting high GS expression and 20% exhibiting low GS expression, and the rest showing moderate expression.[11] Therefore, targeting HDAC6 and USP9X might be a valuable therapeutic strategy for GBM patients with high GS expression. This evidence concerns the gene USP9X and glioblastoma.